Contrasting Allurion Technologies (ALUR) and Its Rivals

Allurion Technologies (NYSE:ALURGet Free Report) is one of 223 public companies in the “Surgical & medical instruments” industry, but how does it contrast to its peers? We will compare Allurion Technologies to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings.


This table compares Allurion Technologies and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allurion Technologies -117.30% N/A -85.06%
Allurion Technologies Competitors -651.10% -139.25% -28.60%

Analyst Ratings

This is a summary of recent recommendations and price targets for Allurion Technologies and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allurion Technologies 0 0 2 0 3.00
Allurion Technologies Competitors 1498 4096 7975 202 2.50

Allurion Technologies presently has a consensus target price of $5.00, suggesting a potential upside of 224.68%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.91%. Given Allurion Technologies’ stronger consensus rating and higher probable upside, equities analysts clearly believe Allurion Technologies is more favorable than its peers.

Volatility & Risk

Allurion Technologies has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Allurion Technologies’ peers have a beta of 0.61, suggesting that their average stock price is 39% less volatile than the S&P 500.

Valuation & Earnings

This table compares Allurion Technologies and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Allurion Technologies $53.47 million -$80.61 million -0.41
Allurion Technologies Competitors $915.69 million $6.47 million -4,907.59

Allurion Technologies’ peers have higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

21.4% of Allurion Technologies shares are owned by institutional investors. Comparatively, 47.7% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 20.0% of Allurion Technologies shares are owned by insiders. Comparatively, 15.3% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.


Allurion Technologies beats its peers on 7 of the 13 factors compared.

Allurion Technologies Company Profile

(Get Free Report)

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with's FREE daily email newsletter.